NPPA notified regarding the computation of the retail price of Ceftriaxone Sodium IP Eq. to Ceftriaxone 1000 mg + Disodium Edetate IP 37 mg + Sulbactam Sodium IP Eq. to Sulbactam 500 mg for M/S BDR Pharmaceuticals International Pvt. Ltd. (Manufacturer) and M/S. Aristo Pharmaceuticals Pvt. Ltd. (Marketer)

Feb 24, 2025 | by TeamLease RegTech Legal Research Team

Free Legal updates for the week 00


Industry Specific Complianceclass="MsoNormal" style="text-align: justify;">The National Pharmaceutical Pricing Authority (NPPA) on February 21, 2025, notified regarding the computation of the retail price of Ceftriaxone Sodium IP Eq. to Ceftriaxone 1000 mg + Disodium Edetate IP 37 mg + Sulbactam Sodium IP Eq. to Sulbactam 500 mg for M/S BDR Pharmaceuticals International Pvt. Ltd. (Manufacturer) and M/S. Aristo Pharmaceuticals Pvt. Ltd. (Marketer)

It states that the price of each Vial containing:- Ceftriaxone Sodium IP Eq. to Ceftriaxone 1000 mg + Disodium Edetate IP 37 mg + Sulbactam Sodium IP Eq. to Sulbactam 500 mg for M/S BDR Pharmaceuticals International Pvt. Ltd. (Manufacturer) and M/S. Aristo Pharmaceuticals Pvt. Ltd. (Marketer) has been revised to Rs. 515.57/-.

[Notification no: 19(4465)/2025/DP/NPPA/Div.II]


Bookmark

Related Updates



Alternate Text

Get updates on the go on RegUpdate Mobile App.

NEW  ·  AI ASSISTANT